China Biopharma Receives Order to Export Flu Vaccine to Macedonia.

HANGZHOU, China -- China Biopharma Inc. (OTCBB: TEDG) today announced that Zhejiang Tianyuan Biotech, the Company's China subsidiary, has received an export letter of credit from the Government of Macedonia to ship its flu vaccine product to this Southeastern European country for distribution.

The order represents the first exportation of the flu vaccine to Macedonia from China. Moreover, this marks the first exportation of a flu vaccine product by Zhejiang Tianyuan.

"We are very pleased to extend the sales channel of our flu vaccine beyond China," said Dr. Jean-Denis Shu, chief executive officer and chief scientist of China Biopharma's China operation. "We believe this sale demonstrates that there is demand and acceptance for our product beyond China's borders. Consequently, we plan to continue to register our product in other countries to expand our international distribution channel."

About China Biopharma Inc.

China Biopharma (formerly Techedge Inc.) is a fast growing developer, producer and distributor of biopharmaceutical products in China. Through its wholly owned subsidiary, China Biopharma Limited, the Company owns the majority interest of Zhejiang Tianyuan Biotech Co., Ltd. The Company's current products consist of human vaccines against influenza, epidemic hemorrhagic fever (HFV), and Japanese Encephalitis (JEV). With its investment and ownership of local Chinese biopharmaceutical companies, the Company plans to build a leading biopharmaceutical company in China by leveraging its manufacturing and marketing capabilities and introducing advanced technologies, best products, and an experienced management team. With a fast growing market, newly completed production facilities, and several other new vaccines in the pipeline, the Company expects to see steady business growth in the near future. For more information, visit its website at www.chinabiopharma.com.cn.

Safe Harbor Statement

Some of the statements made in this press release discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.